Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Zogenix initiated with a Buy at UBS » 06:31
09/09/21
09/09
06:31
09/09/21
06:31
ZGNX

Zogenix

$14.60 /

-0.145 (-0.98%)

UBS analyst Esther…

UBS analyst Esther Rajavelu initiated coverage of Zogenix with a Buy rating and $23 price target. The topline growth prospects for the company, driven by lead drug Fintepla, are not captured at current levels, the analyst tells investors in a research note. Rajavelu expects Zogenix to generate more sales momentum from the potential approval for use in LGS in 2022 as well as its management's strategy to "call on a broader set of prescribers".

ShowHide Related Items >><<
ZGNX Zogenix
$14.60 /

-0.145 (-0.98%)

ZGNX Zogenix
$14.60 /

-0.145 (-0.98%)

08/06/21 Citi
Zogenix price target lowered to $20 from $23 at Citi
05/07/21 Mizuho
Zogenix shares at 'very attractive entry point,' says Mizuho
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
ZGNX Zogenix
$14.60 /

-0.145 (-0.98%)

Hot Stocks
Zogenix receives Orphan Drug Designation for FINTEPLA in Japan » 08:03
08/26/21
08/26
08:03
08/26/21
08:03
ZGNX

Zogenix

$14.47 /

+0.18 (+1.26%)

Zogenix announced that…

Zogenix announced that the Japanese Ministry of Health, Labour & Welfare has granted Orphan Drug Designation to FINTEPLA oral solution, which Zogenix is developing in Japan as a potential treatment for seizures associated with Dravet syndrome. Zogenix is on track to submit a J-NDA for FINTEPLA for the treatment of seizures associated with Dravet syndrome later this year. If approved, the product will be made available in Japan through an exclusive distribution agreement with Nippon Shinyaku. "The orphan drug designation of FINTEPLA in Japan is an important milestone in our mission to meet the unmet needs of severe, rare epilepsy patients around the world," said Stephen Farr, Ph.D., President and Chief Executive Officer of Zogenix. "We are proud to have worked with patients, physicians, and regulators in Japan to achieve this milestone and reinforce our commitment to working with the MHLW to bring this much-needed potential treatment option to patients and families living with Dravet syndrome in Japan."

ShowHide Related Items >><<
ZGNX Zogenix
$14.47 /

+0.18 (+1.26%)

ZGNX Zogenix
$14.47 /

+0.18 (+1.26%)

08/06/21 Citi
Zogenix price target lowered to $20 from $23 at Citi
05/07/21 Mizuho
Zogenix shares at 'very attractive entry point,' says Mizuho
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
ZGNX Zogenix
$14.47 /

+0.18 (+1.26%)

Over a month ago
Conference/Events
Stifel biotech analysts to hold an analyst/industry conference call » 12:50
08/12/21
08/12
12:50
08/12/21
12:50
XENE

Xenon Pharmaceuticals

$17.55 /

-1.07 (-5.75%)

, CERE

Cerevel Therapeutics

$25.08 /

+0.15 (+0.60%)

, ZGNX

Zogenix

$13.40 /

-0.06 (-0.45%)

, JAZZ

Jazz Pharmaceuticals

$144.80 /

-0.21 (-0.14%)

, GWPH

GW Pharmaceuticals

$219.01 /

+ (+0.00%)

Biotech Analysts Matteis…

Biotech Analysts Matteis and Samimy, along with Drs. Cooper, Davis and Kothare, preview the prospects for Xenon Pharmaceuticals' XEN1101 and Cerevel Therapeutics' Darigabat in focal seizures, launch dynamics and trajectory for Zogenix's Fintepla, the next leg of growth for Epidiolex on an Analyst/Industry conference call to be held on August 12 at 1 pm. Webcast Link

ShowHide Related Items >><<
ZGNX Zogenix
$13.40 /

-0.06 (-0.45%)

XENE Xenon Pharmaceuticals
$17.55 /

-1.07 (-5.75%)

JAZZ Jazz Pharmaceuticals
$144.80 /

-0.21 (-0.14%)

GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

CERE Cerevel Therapeutics
$25.08 /

+0.15 (+0.60%)

XENE Xenon Pharmaceuticals
$17.55 /

-1.07 (-5.75%)

10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
CERE Cerevel Therapeutics
$25.08 /

+0.15 (+0.60%)

07/13/21 Stifel
Cerevel Therapeutics price target raised to $33 from $21 at Stifel
06/30/21 Citi
Karuna Therapeutics selloff brings buying opportunity, says Citi
06/30/21 Mizuho
Karuna selloff on Cerevel data 'appears overdone,' says Mizuho
06/18/21 Morgan Stanley
Cerevel Therapeutics initiated with an Overweight at Morgan Stanley
ZGNX Zogenix
$13.40 /

-0.06 (-0.45%)

08/06/21 Citi
Zogenix price target lowered to $20 from $23 at Citi
05/07/21 Mizuho
Zogenix shares at 'very attractive entry point,' says Mizuho
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
JAZZ Jazz Pharmaceuticals
$144.80 /

-0.21 (-0.14%)

07/23/21 RBC Capital
Jazz Pharmaceuticals price target raised to $216 from $190 at RBC Capital
07/15/21 JPMorgan
JPMorgan stays bullish on Jazz Pharmaceuticals after physician survey
07/08/21 Piper Sandler
Piper neurologist survey encouraging for Jazz Pharmaceuticals
06/22/21 Barclays
Jazz Pharmaceuticals price target raised to $250 from $235 at Barclays
GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

04/14/21 Stifel
Jazz Pharmaceuticals price target raised to $202 from $195 at Stifel
02/05/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $207 from $195 at H.C. Wainwright
02/04/21 SVB Leerink
GW Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
02/04/21
GW Pharmaceuticals downgraded to Neutral from Buy at Citi
ZGNX Zogenix
$13.40 /

-0.06 (-0.45%)

XENE Xenon Pharmaceuticals
$17.55 /

-1.07 (-5.75%)

JAZZ Jazz Pharmaceuticals
$144.80 /

-0.21 (-0.14%)

GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

CERE Cerevel Therapeutics
$25.08 /

+0.15 (+0.60%)

  • 02
    Jul
  • 10
    Mar
JAZZ Jazz Pharmaceuticals
$144.80 /

-0.21 (-0.14%)

XENE Xenon Pharmaceuticals
$17.55 /

-1.07 (-5.75%)

JAZZ Jazz Pharmaceuticals
$144.80 /

-0.21 (-0.14%)

CERE Cerevel Therapeutics
$25.08 /

+0.15 (+0.60%)

GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

CERE Cerevel Therapeutics
$25.08 /

+0.15 (+0.60%)

Conference/Events
Stifel biotech analysts to hold an analyst/industry conference call » 04:55
08/12/21
08/12
04:55
08/12/21
04:55
XENE

Xenon Pharmaceuticals

$18.69 /

+1.69 (+9.94%)

, CERE

Cerevel Therapeutics

$24.97 /

-0.61 (-2.38%)

, ZGNX

Zogenix

$13.46 /

-0.63 (-4.47%)

, JAZZ

Jazz Pharmaceuticals

$145.06 /

+0.42 (+0.29%)

, GWPH

GW Pharmaceuticals

$219.01 /

+ (+0.00%)

Biotech Analysts Matteis…

Biotech Analysts Matteis and Samimy, along with Drs. Cooper, Davis and Kothare, preview the prospects for Xenon Pharmaceuticals' XEN1101 and Cerevel Therapeutics' Darigabat in focal seizures, launch dynamics and trajectory for Zogenix's Fintepla, the next leg of growth for Epidiolex on an Analyst/Industry conference call to be held on August 12 at 1 pm. Webcast Link

ShowHide Related Items >><<
ZGNX Zogenix
$13.46 /

-0.63 (-4.47%)

XENE Xenon Pharmaceuticals
$18.69 /

+1.69 (+9.94%)

JAZZ Jazz Pharmaceuticals
$145.06 /

+0.42 (+0.29%)

GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

CERE Cerevel Therapeutics
$24.97 /

-0.61 (-2.38%)

XENE Xenon Pharmaceuticals
$18.69 /

+1.69 (+9.94%)

10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
CERE Cerevel Therapeutics
$24.97 /

-0.61 (-2.38%)

07/13/21 Stifel
Cerevel Therapeutics price target raised to $33 from $21 at Stifel
06/30/21 Citi
Karuna Therapeutics selloff brings buying opportunity, says Citi
06/30/21 Mizuho
Karuna selloff on Cerevel data 'appears overdone,' says Mizuho
06/18/21 Morgan Stanley
Cerevel Therapeutics initiated with an Overweight at Morgan Stanley
ZGNX Zogenix
$13.46 /

-0.63 (-4.47%)

08/06/21 Citi
Zogenix price target lowered to $20 from $23 at Citi
05/07/21 Mizuho
Zogenix shares at 'very attractive entry point,' says Mizuho
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
JAZZ Jazz Pharmaceuticals
$145.06 /

+0.42 (+0.29%)

07/23/21 RBC Capital
Jazz Pharmaceuticals price target raised to $216 from $190 at RBC Capital
07/15/21 JPMorgan
JPMorgan stays bullish on Jazz Pharmaceuticals after physician survey
07/08/21 Piper Sandler
Piper neurologist survey encouraging for Jazz Pharmaceuticals
06/22/21 Barclays
Jazz Pharmaceuticals price target raised to $250 from $235 at Barclays
GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

04/14/21 Stifel
Jazz Pharmaceuticals price target raised to $202 from $195 at Stifel
02/05/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $207 from $195 at H.C. Wainwright
02/04/21 SVB Leerink
GW Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
02/04/21
GW Pharmaceuticals downgraded to Neutral from Buy at Citi
ZGNX Zogenix
$13.46 /

-0.63 (-4.47%)

XENE Xenon Pharmaceuticals
$18.69 /

+1.69 (+9.94%)

JAZZ Jazz Pharmaceuticals
$145.06 /

+0.42 (+0.29%)

GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

CERE Cerevel Therapeutics
$24.97 /

-0.61 (-2.38%)

  • 02
    Jul
  • 10
    Mar
JAZZ Jazz Pharmaceuticals
$145.06 /

+0.42 (+0.29%)

XENE Xenon Pharmaceuticals
$18.69 /

+1.69 (+9.94%)

JAZZ Jazz Pharmaceuticals
$145.06 /

+0.42 (+0.29%)

CERE Cerevel Therapeutics
$24.97 /

-0.61 (-2.38%)

GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

CERE Cerevel Therapeutics
$24.97 /

-0.61 (-2.38%)

Conference/Events
Stifel biotech analysts to hold an analyst/industry conference call » 15:18
08/10/21
08/10
15:18
08/10/21
15:18
XENE

Xenon Pharmaceuticals

$17.00 /

+0.59 (+3.60%)

, CERE

Cerevel Therapeutics

$25.77 /

+0.42 (+1.66%)

, ZGNX

Zogenix

$14.13 /

-0.73 (-4.91%)

, JAZZ

Jazz Pharmaceuticals

$144.50 /

-6.59 (-4.36%)

, GWPH

GW Pharmaceuticals

$219.01 /

+ (+0.00%)

Biotech Analysts Matteis…

Biotech Analysts Matteis and Samimy, along with Drs. Cooper, Davis and Kothare, preview the prospects for Xenon Pharmaceuticals' XEN1101 and Cerevel Therapeutics' Darigabat in focal seizures, launch dynamics and trajectory for Zogenix's Fintepla, the next leg of growth for Epidiolex on an Analyst/Industry conference call to be held on August 12 at 1 pm. Webcast Link

ShowHide Related Items >><<
ZGNX Zogenix
$14.13 /

-0.73 (-4.91%)

XENE Xenon Pharmaceuticals
$17.00 /

+0.59 (+3.60%)

JAZZ Jazz Pharmaceuticals
$144.50 /

-6.59 (-4.36%)

GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

CERE Cerevel Therapeutics
$25.77 /

+0.42 (+1.66%)

XENE Xenon Pharmaceuticals
$17.00 /

+0.59 (+3.60%)

10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
10/02/20 SVB Leerink
Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink
CERE Cerevel Therapeutics
$25.77 /

+0.42 (+1.66%)

07/13/21 Stifel
Cerevel Therapeutics price target raised to $33 from $21 at Stifel
06/30/21 Citi
Karuna Therapeutics selloff brings buying opportunity, says Citi
06/30/21 Mizuho
Karuna selloff on Cerevel data 'appears overdone,' says Mizuho
06/18/21 Morgan Stanley
Cerevel Therapeutics initiated with an Overweight at Morgan Stanley
ZGNX Zogenix
$14.13 /

-0.73 (-4.91%)

08/06/21 Citi
Zogenix price target lowered to $20 from $23 at Citi
05/07/21 Mizuho
Zogenix shares at 'very attractive entry point,' says Mizuho
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
JAZZ Jazz Pharmaceuticals
$144.50 /

-6.59 (-4.36%)

07/23/21 RBC Capital
Jazz Pharmaceuticals price target raised to $216 from $190 at RBC Capital
07/15/21 JPMorgan
JPMorgan stays bullish on Jazz Pharmaceuticals after physician survey
07/08/21 Piper Sandler
Piper neurologist survey encouraging for Jazz Pharmaceuticals
06/22/21 Barclays
Jazz Pharmaceuticals price target raised to $250 from $235 at Barclays
GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

04/14/21 Stifel
Jazz Pharmaceuticals price target raised to $202 from $195 at Stifel
02/05/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $207 from $195 at H.C. Wainwright
02/04/21 SVB Leerink
GW Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
02/04/21
GW Pharmaceuticals downgraded to Neutral from Buy at Citi
ZGNX Zogenix
$14.13 /

-0.73 (-4.91%)

XENE Xenon Pharmaceuticals
$17.00 /

+0.59 (+3.60%)

JAZZ Jazz Pharmaceuticals
$144.50 /

-6.59 (-4.36%)

GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

CERE Cerevel Therapeutics
$25.77 /

+0.42 (+1.66%)

  • 02
    Jul
  • 10
    Mar
JAZZ Jazz Pharmaceuticals
$144.50 /

-6.59 (-4.36%)

XENE Xenon Pharmaceuticals
$17.00 /

+0.59 (+3.60%)

JAZZ Jazz Pharmaceuticals
$144.50 /

-6.59 (-4.36%)

CERE Cerevel Therapeutics
$25.77 /

+0.42 (+1.66%)

GWPH GW Pharmaceuticals
$219.01 /

+ (+0.00%)

CERE Cerevel Therapeutics
$25.77 /

+0.42 (+1.66%)

Recommendations
Zogenix price target lowered to $20 from $23 at Citi » 05:30
08/06/21
08/06
05:30
08/06/21
05:30
ZGNX

Zogenix

$16.53 /

+0.36 (+2.23%)

Citi analyst Neena…

Citi analyst Neena Bitritto-Garg lowered the firm's price target on Zogenix to $20 from $23 and keeps a Neutral rating on the shares. After three full quarters of Fintepla launch, signs continue to point to a challenging launch, Bitritto-Garg tells investors in a research note.

ShowHide Related Items >><<
ZGNX Zogenix
$16.53 /

+0.36 (+2.23%)

ZGNX Zogenix
$16.53 /

+0.36 (+2.23%)

05/07/21 Mizuho
Zogenix shares at 'very attractive entry point,' says Mizuho
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
ZGNX Zogenix
$16.53 /

+0.36 (+2.23%)

Earnings
Zogenix reports Q2 EPS ($1.05), consensus (94c) » 16:18
08/05/21
08/05
16:18
08/05/21
16:18
ZGNX

Zogenix

$16.53 /

+0.36 (+2.23%)

Reports Q2 revenue…

Reports Q2 revenue $18.79M, consensus $17.08M."We are encouraged by the continued momentum of our launch of FINTEPLA(R) in Dravet syndrome in the U.S. and Europe and remain focused on driving broader adoption of FINTEPLA as in-person physician visits increase and physicians and families move forward with new treatment decisions," said Stephen Farr, president and CEO of Zogenix.

ShowHide Related Items >><<
ZGNX Zogenix
$16.53 /

+0.36 (+2.23%)

ZGNX Zogenix
$16.53 /

+0.36 (+2.23%)

05/07/21 Mizuho
Zogenix shares at 'very attractive entry point,' says Mizuho
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
ZGNX Zogenix
$16.53 /

+0.36 (+2.23%)

Hot Stocks
Zogenix's FINTEPLA recognized by clinicians in editorial » 08:10
07/21/21
07/21
08:10
07/21/21
08:10
ZGNX

Zogenix

$16.84 /

+0.83 (+5.18%)

Zogenix announced that…

Zogenix announced that its product FINTEPLA oral solution has been recognized by two distinguished clinicians in an Epilepsy & Behavior editorial titled "Raising the Bar: Fenfluramine Sets New Treatment Standards for Dravet Syndrome." In the editorial, the authors, Joseph Sullivan, M.D., of the UCSF Benioff Children's Hospitals, and Helen Cross, M.B.,Ch.B. Ph.D., of the UK's UCL Institute of Child Health, note that the treatment and diagnosis of severe, rare epilepsies such as Dravet syndrome have improved in the U.S. and Europe with earlier accurate diagnosis, better access to a network of specialized medical care, and availability of new medications. In particular, they note that FINTEPLA has achieved responder rates for seizure reduction at the greater than/=75% level that were previously only observed at the greater than/= 50% level. In their assessment, the authors write that future Dravet syndrome treatments "should be evaluated against the demonstrated efficacy of fenfluramine." FINTEPLA was approved in the U.S. and European Union in 2020 for the treatment of seizures associated with Dravet syndrome patients aged two years and older. The authors write that the novel outcomes reported with FINTEPLA treatment, such as effects on executive functions, have effectively raised the bar for assessment of future therapies. Their opinion is based on the body of previously released data from the clinical trials that supported the U.S. and EU regulatory reviews, as well as data from patients treated up to three years in an ongoing open-label study and in early access programs. Across studies, the data demonstrate that FINTEPLA provides safe, effective, and durable seizure reduction for a majority of treated Dravet syndrome patients, including those who, prior to treatment with FINTEPLA, had continued to experience a high seizure burden despite treatment with one or more other antiepileptic medicines.Across studies, FINTEPLA has been generally well-tolerated, with no observed cases of pulmonary arterial hypertension or valvular heart disease. The most common adverse events were reported as decreased appetite, fatigue, diarrhea, and pyrexia.

ShowHide Related Items >><<
ZGNX Zogenix
$16.84 /

+0.83 (+5.18%)

ZGNX Zogenix
$16.84 /

+0.83 (+5.18%)

05/07/21 Mizuho
Zogenix shares at 'very attractive entry point,' says Mizuho
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
ZGNX Zogenix
$16.84 /

+0.83 (+5.18%)

ZGNX Zogenix
$16.84 /

+0.83 (+5.18%)

Over a quarter ago
Recommendations
Zogenix shares at 'very attractive entry point,' says Mizuho » 06:46
05/07/21
05/07
06:46
05/07/21
06:46
ZGNX

Zogenix

$17.47 /

-0.03 (-0.17%)

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang says Zogenix is trading at a "very attractive entry point" following a "solid" Q1 print. The U.S. launch of Fintepla in Dravet syndrome continues to progress well and launch momentum will be further aided by the reopening of states as Covid-19 subsides, Yang tells investors in a research note. The analyst affirms a Buy rating on the shares with a $55 price target.

ShowHide Related Items >><<
ZGNX Zogenix
$17.47 /

-0.03 (-0.17%)

ZGNX Zogenix
$17.47 /

-0.03 (-0.17%)

04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
ZGNX Zogenix
$17.47 /

-0.03 (-0.17%)

ZGNX Zogenix
$17.47 /

-0.03 (-0.17%)

ZGNX Zogenix
$17.47 /

-0.03 (-0.17%)

Hot Stocks
Zogenix launches Global Access Program for FINTEPLA oral solution » 08:15
04/27/21
04/27
08:15
04/27/21
08:15
ZGNX

Zogenix

$19.25 /

+0.205 (+1.08%)

Zogenix announced the…

Zogenix announced the launch of its new global access program for FINTEPLA oral solution. FINTEPLA was approved in the U.S. and European Union in 2020 as an add-on therapy for the treatment of seizures associated with a debilitating rare epilepsy called Dravet syndrome in patients aged two years and older. The Zogenix Access Program expands access for physicians in other parts of the world, where local regulations allow, including European countries where reimbursement has not yet been established. Zogenix has partnered with Durbin, a part of Uniphar Group's Product Access Division and a leading specialist in the international distribution of specialized pharmaceuticals, to manage the Zogenix Access Program for FINTEPLA. Durbin has extensive global experience providing, high-quality support while adhering to complex local requirements.

ShowHide Related Items >><<
ZGNX Zogenix
$19.25 /

+0.205 (+1.08%)

ZGNX Zogenix
$19.25 /

+0.205 (+1.08%)

04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
ZGNX Zogenix
$19.25 /

+0.205 (+1.08%)

ZGNX Zogenix
$19.25 /

+0.205 (+1.08%)

ZGNX Zogenix
$19.25 /

+0.205 (+1.08%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.